HomeGeneticsGeneDOK7 gene
Back to Gene
DOK7 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

DOK7 gene

The DOK7 gene provides instructions for making a protein essential for forming and maintaining the connections between nerve and muscle cells.

Overview

The DOK7 gene provides instructions for making a protein that helps form connections between nerve cells and muscle cells at the neuromuscular junction. This junction is the critical area where signals are passed from nerves to muscles to trigger movement.

The Dok-7 protein participates in activating a protein called MuSK, which organizes proteins necessary for the neuromuscular junction. Specifically, MuSK helps gather the acetylcholine receptor (AChR) on the surface of muscle cells, which is vital for signaling between nerve and muscle cells.

Health Conditions Related to Genetic Changes

Congenital myasthenic syndromes

Variants (mutations) in the DOK7 gene are known to cause congenital myasthenic syndromes. These conditions are characterized by muscle weakness that tires easily (myasthenia), typically beginning shortly after birth or in early childhood.

  • Variants cause the production of an altered Dok-7 protein that cannot activate MuSK.
  • This leads to reduced levels of AChR at the neuromuscular junction.
  • Reduced signaling between nerve and muscle cells results in decreased muscle movement and characteristic muscle weakness.

Other disorders

In rare cases, DOK7 variants cause fetal akinesia deformation sequence. This severe condition is characterized by a lack of movement before birth, which leads to joint stiffness (arthrogryposis).

  • Affected individuals often experience slow growth before birth, underdevelopment of the lungs (pulmonary hypoplasia), and a cleft palate.
  • This condition is typically fatal before birth.
  • The variants result in a nonfunctional version of the Dok-7 protein, impairing nerve-to-muscle signaling.

Genomic Location

The DOK7 gene is found on chromosome 4.

Frequently Asked Questions

DOK7‑related CMS often presents with limb‑girdle weakness that worsens with activity but improves after brief rest, and it typically shows a poor or paradoxical response to acetylcholinesterase inhibitors (e.g., pyridostigmine). Electromyography may reveal a decremental response that does not improve with cholinesterase drugs. Genetic testing—either a CMS panel or whole‑exome sequencing—identifies pathogenic DOK7 variants and confirms the diagnosis.
Patients with DOK7 mutations usually do not benefit from pyridostigmine; in fact, it can worsen weakness. The first‑line agents are β2‑adrenergic agonists such as salbutamol or ephedrine, which enhance neuromuscular transmission by increasing cyclic AMP in muscle cells. Clinical trials have shown significant strength gains and improved endurance with these drugs, often at low oral doses.
With early initiation of β2‑agonist therapy and supportive measures (physical therapy, respiratory monitoring), most children achieve near‑normal motor development and avoid severe respiratory crises. However, some individuals may retain mild residual weakness into adulthood. Regular follow‑up with a neuromuscular specialist is essential to adjust medication doses and monitor for side effects.
Yes. Once the specific pathogenic DOK7 variant is identified in a family member, targeted carrier testing can be offered to the parents. For future pregnancies, chorionic villus sampling (10‑12 weeks) or amniocentesis (15‑18 weeks) can test fetal DNA for the mutation. Alternatively, couples may pursue pre‑implantation genetic diagnosis (PGD) with in‑vitro fertilization to select embryos without the DOK7 mutation. Genetic counseling should be arranged before any testing.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab

Sök
Om ossVillkor och policyVanliga frågorKontakta oss